Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255193 | 1.00 | GCK (0.74) | GCKKCNH2 | |
| SCHEMBL2666294 | 0.92 | GCK (0.71) | GCKKCNH2 | |
| SCHEMBL1146517 | 0.92 | GCK (0.71) | GCKKCNH2 | |
| SCHEMBL29395307 | 0.92 | GCK (0.75) | GCKKCNH2 | |
| SCHEMBL2659206 | 0.92 | GCK (0.75) | GCKKCNH2 | |
| SCHEMBL2957869 | 0.92 | GCK (0.75) | GCKKCNH2 | |
| SCHEMBL13255190 | 0.91 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL3606646 | 0.91 | GCK (0.79) | GCKKCNH2 | |
| Hydrochloric Acid SCHEMBL3604100 | 0.91 | GCK (0.74) | GCKKCNH2 | |
| SCHEMBL3605878 | 0.89 | GCK (0.77) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | claimed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | claimed |
| EP-1600442-B1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | MSD KK (JP) | 2018-01-17 | — | — | EP | disclosed |
| EP-1600442-B1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | MSD KK (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | GCK, GCKR, KHK | GCK 1/4885KCNH2 470/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | GCK 1/4885KCNH2 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.